Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a devastating lung condition.
The post Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval appeared first on Investor's Business Daily.